多囊卵巢综合征患者的胰岛素抵抗
stic ovary syndrome by activating its own receptor and using inositolgl
ycan mediators as the signal transduction system. J Clin Endocrinol Met
ab, 1998 ,83:2001-2005.
10 Zhang L, Rodriguez H, Ohno S, et al. Serine phosphorylation of hu
man P450c17 increases 17,20 lyase activity:implications for adrenache a
nd polycystic ovary syndrome. Proc Natl Acad Sci USA,1995,92:10619-106
23.
11 Nestler JE. Role of hyperinsulinemia in the pathogenesis of the p
olycystic ovary syndrome, and its clinical implications. Semin Reprod E
ndocrinol, 1997,15:111 -122.
12 Azziz R, Rittmaster RS, Fox LM, et al. Role of the ovary in the a
drenal excess of hy- perandrogenic women. Fertil Steril, 1998,69:691-6
96.
13 Chavez-Ross A, Franks S, Mason HD,&
nbsp;et al. Modeling the control of
ovulation and polycystic ovary syndrome. J Math Biol, 1997,36:95-118.
14 Mason H, Franks S. Local control of ovarian steroidogenesis. Bail
lieres Clin Obstet Gynecol, 1997,11:261-279.
15 吴效科,张祖暄,苏延华.多囊卵巢综合征患者垂体-卵巢、肾上腺、甲状腺功
能的研究.中华妇产科杂志,1998,33:153-156.
16 吴效科,张祖暄,苏延华.多囊卵巢综合征患者脂代谢的研究.中华妇产科杂志
,1998,33:25-27.
17 Minshall RD, Stanczyk FZ, Miyahawa K, et al. Ovarian steroid prot
ection againat coronary artery hyperreactivity in Rhesus monkey. J Clin
Endocrinol Metab,1998,83: 649-659.
18 Reaven GM. Pathophysiology of insulin resis- tance in human disea
se. Physiol Rev, 1995,75:473-486.
19 Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al. Therapeutic
effects of metformin on insulin resistance and hyperandrogenism in poly
cystic ovary syndrome. Eur J Endocrinol, 1998;138:269-274.
20 Park KS, Ciarakdi TP, Abrams-Carter L, et al. Troglitazone regula
tion of glucose metabolism in human skeletal muscle culture from obese
type 2 diabetes subjects. J Clin Endocrinol Metab, 1998,83:1636-1643.
《多囊卵巢综合征患者的胰岛素抵抗(第4页)》